SCF ubiquitin ligases in the maintenance of genome stability

Trends in Biochemical Sciences

Volumn 37, Issue 2, 2012, Pages 66-73

  Silverman, Joshua S ^a   Skaar, Jeffrey R ^a   Pagano, Michele ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; F BOX PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANEUPLOIDY; CELL CYCLE ARREST; CENTROSOME; CHROMOSOME SEGREGATION; DNA DAMAGE; DNA REPAIR; EUKARYOTIC CELL; GENE DUPLICATION; GENOMIC INSTABILITY; GENOTOXICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; REVIEW; RING FINGER MOTIF; UBIQUITINATION;

ANIMALS; DNA DAMAGE; GENOMIC INSTABILITY; HUMANS; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITINATION;

EUKARYOTA;

EID: 84856709112     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2011.10.004     Document Type: Review

References (85)

1. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
2. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
3. Hoare M., et al. Ageing, telomeres, senescence, and liver injury. J. Hepatol. 2010, 53:950-961.
4. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15:2177-2196.
5. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
6. Polo S.E., Jackson S.P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 2011, 25:409-433.
7. Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol. Cell 2010, 40:179-204.
8. Bakkenist C.J., Kastan M.B. Initiating cellular stress responses. Cell 2004, 118:9-17.
9. Derheimer F.A., Kastan M.B. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett. 2010, 584:3675-3681.
10. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 2007, 8:379-393.
11. Fang X., Zhang P. Aneuploidy and tumorigenesis. Semin. Cell Dev. Biol. 2011, 22:595-601.
12. Tanaka K., Hirota T. Chromosome segregation machinery and cancer. Cancer Sci. 2009, 100:1158-1165.
13. Lingle W.L., et al. Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv. Exp. Med. Biol. 2005, 570:393-421.
14. Duensing A., Duensing S. Centrosomes, polyploidy and cancer. Adv. Exp. Med. Biol. 2010, 676:93-103.
15. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
16. Schwartz A.L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 1999, 50:57-74.
17. Deshaies R.J., Joazeiro C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78:399-434.
18. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
19. Skaar J.R., Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr. Opin. Cell Biol. 2009, 21:816-824.
20. Cardozo T., Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 2004, 5:739-751.
21. Jin J., et al. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004, 18:2573-2580.
22. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
23. Busino L., et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 2003, 426:87-91.
24. β-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 2003, 17:3062-3074.
25. β-TRCP -dependent degradation for cell cycle arrest. Mol. Biol. Cell 2009, 20:2186-2195.
26. Jin J., et al. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase. J. Biol. Chem. 2008, 283:19322-19328.
27. Honaker Y., Piwnica-Worms H. Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene 2010, 29:3324-3334.
28. Myer D.L., et al. The Plk3-Cdc25 circuit. Oncogene 2005, 24:299-305.
29. Zimmerman W.C., Erikson R.L. Polo-like kinase 3 is required for entry into S phase. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1847-1852.
30. Melixetian M., et al. NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat. Cell Biol. 2009, 11:1247-1253.
31. Sorensen C.S., et al. NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling. Cell Cycle 2010, 9:450-455.
32. 2-terminal kinase and p38 target Cdc25B for degradation. Cancer Res. 2009, 69:6438-6444.
33. Kanemori Y., et al. β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:6279-6284.
34. Xia Y., et al. Phosphorylation of p53 by IκB kinase 2 promotes its degradation by β-TrCP. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2629-2634.
35. β-TRCP ubiquitin ligase. Cancer Cell 2010, 18:147-159.
36. Cheng Q., Chen J. The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation. Cell Cycle 2011, 10:1162-1166.
37. Kim J.K., Diehl J.A. Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 2009, 220:292-296.
38. Pagano M., et al. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 1994, 8:1627-1639.
39. Lukas J., et al. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994, 9:707-718.
40. Agami R., Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000, 102:55-66.
41. Barbash O., et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 2008, 14:68-78.
42. crystallin complex. Mol. Cell 2006, 24:355-366.
43. Okabe H., et al. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 2006, 1:e128.
44. Pawar S.A., et al. C/EBPδ targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9210-9215.
45. Santra M.K., et al. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 2009, 459:722-725.
46. Fbx4/alphaαB-crystallin E3 ligase: when one is not enough. Cell Cycle 2008, 7:2983-2986.
47. Fbx4 dimerization and activity involves a novel component, 14-3-3e{open}. Oncogene 2011, 30:1995-2002.
48. Fbx4 ubiquitin ligase. J. Biol. Chem. 2010, 285:13896-13906.
49. Lee T.H., et al. The F-box protein FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere maintenance. J. Biol. Chem. 2006, 281:759-768.
50. Vaites L.P., et al. The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol. Cell. Biol. 2011, 31:4513-4523.
51. Pontano L.L., et al. Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol. Cell. Biol. 2008, 28:7245-7258.
52. Macurek L., et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123.
53. Bassermann F., et al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008, 134:256-267.
54. Seki A., et al. Plk1- and β-TrCP-dependent degradation of Bora controls mitotic progression. J. Cell Biol. 2008, 181:65-78.
55. β-TrCP. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4419-4424.
56. β-TrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol. Cell 2006, 23:319-329.
57. Mamely I., et al. Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr. Biol. 2006, 16:1950-1955.
58. β-TrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol. Cell 2006, 23:307-318.
59. Zhang Y.W., et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell 2005, 19:607-618.
60. Zhang Y.W., et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol. Cell 2009, 35:442-453.
61. Merry C., et al. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010, 9:279-283.
62. Freed E., et al. Components of an SCF ubiquitin ligase localize to the centrosome and regulate the centrosome duplication cycle. Genes Dev. 1999, 13:2242-2257.
63. Piva R., et al. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol. Cell. Biol. 2002, 22:8375-8387.
64. Cyclin F controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 2010, 466:138-142.
65. Puklowski A., et al. The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication. Nat. Cell Biol. 2011, 13:1004-1009.
66. Habedanck R., et al. The Polo kinase Plk4 functions in centriole duplication. Nat. Cell Biol. 2005, 7:1140-1146.
67. Korzeniewski N., et al. Cullin 1 functions as a centrosomal suppressor of centriole multiplication by regulating polo-like kinase 4 protein levels. Cancer Res. 2009, 69:6668-6675.
68. Rogers G.C., et al. The SCF Slimb ubiquitin ligase regulates Plk4/Sak levels to block centriole reduplication. J. Cell Biol. 2009, 184:225-239.
69. Cunha-Ferreira I., et al. The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Curr. Biol. 2009, 19:43-49.
70. Guderian G., et al. Plk4 trans-autophosphorylation regulates centriole number by controlling βTrCP-mediated degradation. J. Cell Sci. 2010, 123:2163-2169.
71. Guardavaccaro D., et al. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev. Cell 2003, 4:799-812.
72. Guardavaccaro D., et al. Control of chromosome stability by the β-TrCP-REST-Mad2 axis. Nature 2008, 452:365-369.
73. β-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008, 452:370-374.
74. Bekker-Jensen S., Mailand N. The ubiquitin- and SUMO-dependent signaling response to DNA double-strand breaks. FEBS Lett. 2011, 585:2914-2919.
75. Matsuoka S., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
76. Yen H.C., Elledge S.J. Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science 2008, 322:923-929.
77. Yen H.C., et al. Global protein stability profiling in mammalian cells. Science 2008, 322:918-923.
78. Welcker M., et al. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr. Biol. 2004, 14:1852-1857.
79. Soucy T.A., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
80. Jia L., Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr. Cancer Drug Targets 2011, 11:347-356.
81. Milhollen M.A., et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma. Blood 2010, 116:1515-1523.
82. Cardozo T., Pagano M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem. 2007, 8(Suppl. 1):S9.
83. Orlicky S., et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol. 2010, 28:733-737.
84. Aghajan M., et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 2010, 28:738-742.
85. Kanie, T. et al. (2011) Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol. Cell. Biol. doi:10.1128/FMCB.06570-11.